Study find loss of certain protein is associated with poor prognosis in breast and lung cancer

on February 3 | in Breast Cancer, Cancer Research & Technology, Featured News, Lung Cancer, News | by | with Comments Off

Oncology News AustraliaMoffitt Cancer Center researchers have found that breast and lung cancer patients who have low levels of a protein called tristetraprolin (TTP) have more aggressive tumours and a poorer prognosis than those with high levels of the protein. Their study was published in the Dec. 26 issue of PLoS One.

Cancer arises through the increased activity of oncogenes, proteins that drive cancer growth, and the decreased activity of tumour suppressors, proteins that block malignant growth and progression. TTP is a recently discovered tumour suppressor protein, and scientists at Moffitt have found that this protein can prevent lymphoma growth in mice.

Researchers wanted to further investigate the importance of TTP in cancer patients and what other genes it is associated with in cancer. Using a detailed catalog of genetic changes in cancer developed by the National Institutes of Health, called The Cancer Genome Atlas, Moffitt scientists compared patients who had low levels of TTP to those with high levels of the protein.

These researchers found a network of 50 different genes associated with low levels of TTP in breast, lung and colon tumours. This genetic network was also present in other tumour types, including prostate, pancreatic and bladder cancer. This demonstrates that TTP is involved in a variety of mechanisms important for tumour development and growth, and suggests that developing agents that target this network may be an effective therapeutic strategy across a wide spectrum of tumours.

They also reported that low levels of TTP were associated with poor prognosis in certain cancers, including a higher rate of relapse in breast cancer patients and lower rates of survival in lung adenocarcinoma patients. Additionally, breast and lung cancer patients with low levels of TTP tended to have more aggressive types of tumours.

“Identifying this network allows us to set up future research projects focused on understanding how TTP functions as a tumour suppressor with the ultimate goal of developing treatments specific for patients that have low levels of TTP,” explained Robert Rounbehler, Ph.D., research scientist at Moffitt.

Source: H. Lee Moffitt Cancer Center & Research Institute

Pin It

Related Posts

Comments are closed.

« »

Scroll to top